PL1620425T3 - Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu - Google Patents

Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu

Info

Publication number
PL1620425T3
PL1620425T3 PL04726965T PL04726965T PL1620425T3 PL 1620425 T3 PL1620425 T3 PL 1620425T3 PL 04726965 T PL04726965 T PL 04726965T PL 04726965 T PL04726965 T PL 04726965T PL 1620425 T3 PL1620425 T3 PL 1620425T3
Authority
PL
Poland
Prior art keywords
glucagon receptor
substituted
receptor antagonists
cyanothiophene
acetamides
Prior art date
Application number
PL04726965T
Other languages
English (en)
Inventor
Shawn David Erickson
Paul Gillespie
Kevin Richard Guertin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL1620425T3 publication Critical patent/PL1620425T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL04726965T 2003-04-16 2004-04-13 Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu PL1620425T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46320003P 2003-04-16 2003-04-16
PCT/EP2004/003884 WO2004092156A1 (en) 2003-04-16 2004-04-13 Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
EP04726965A EP1620425B1 (en) 2003-04-16 2004-04-13 Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists

Publications (1)

Publication Number Publication Date
PL1620425T3 true PL1620425T3 (pl) 2009-06-30

Family

ID=33300050

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04726965T PL1620425T3 (pl) 2003-04-16 2004-04-13 Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu

Country Status (15)

Country Link
US (1) US7138529B2 (pl)
EP (1) EP1620425B1 (pl)
JP (1) JP4599347B2 (pl)
KR (1) KR100779324B1 (pl)
CN (1) CN100398533C (pl)
AT (1) ATE418548T1 (pl)
AU (1) AU2004230220B2 (pl)
BR (1) BRPI0409454A (pl)
CA (1) CA2521732C (pl)
DE (1) DE602004018630D1 (pl)
ES (1) ES2316978T3 (pl)
MX (1) MXPA05010998A (pl)
PL (1) PL1620425T3 (pl)
RU (1) RU2336274C2 (pl)
WO (1) WO2004092156A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2818547B1 (fr) * 2000-12-22 2006-11-17 Oreal Nouveaux derives c-glycosides et utilisation
CA2498106A1 (en) * 2002-09-12 2004-03-25 Merck & Co., Inc. Substituted bicyclic thiophene derivatives, compositions containing such compounds and methods of use
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
DK1753512T3 (da) * 2004-05-28 2008-11-17 4Sc Ag Tetrahydropyridothiophener
CA2568718A1 (en) * 2004-06-04 2005-12-15 Altana Pharma Ag Tetrahydropyridothiophenes for use in the treatment of cancer
US20090209534A1 (en) * 2004-06-11 2009-08-20 Klaus Pekari Novel compounds and use of tetrahydropyridopyridothiophenes
CA2569623A1 (en) * 2004-06-11 2005-12-22 Altana Pharma Ag Novel compounds and use of tetrahydropyridothiophenes
DE102004051188A1 (de) * 2004-10-21 2006-04-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cyanothiophene, deren Herstellung und deren Verwendung als Arzneimittel
AU2006212224A1 (en) * 2005-02-09 2006-08-17 4Sc Ag Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
AU2006212179A1 (en) * 2005-02-11 2006-08-17 4Sc Ag Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer
US20090252706A1 (en) * 2005-02-11 2009-10-08 Klaus Pekari Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer
CA2609003A1 (en) * 2005-05-25 2006-11-30 Nycomed Gmbh Tetrahydropyridothiophenes for use in the treatment of cancer
EP1893618A2 (en) * 2005-05-25 2008-03-05 Nycomed GmbH Tetrahydropyridothiophenes for use in the treatment of cancer
KR20200123866A (ko) * 2007-02-09 2020-10-30 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
FR2921367B1 (fr) * 2007-09-26 2009-10-30 Servier Lab Nouveau procede de synthese du ranelate de strontium et de ses hydrates
PT2799428T (pt) 2008-08-13 2017-02-17 Metabasis Therapeutics Inc Antagonistas de glicagina
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
MX388871B (es) 2014-06-27 2025-03-20 Nogra Pharma Ltd Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
AU2019291488B2 (en) * 2018-06-19 2022-02-24 Novartis Ag N-substituted tetrahydrothienopyridine derivatives and uses thereof
CN114957278B (zh) * 2021-02-20 2023-08-11 兰州大学 胰高血糖素受体拮抗剂及其用途
CN117343011A (zh) * 2023-09-28 2024-01-05 晨伫(杭州)生物科技有限责任公司 基于吡唑基-磺酰基-苯基骨架结构的化合物及其制备方法和应用、药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206375A (en) * 1985-03-02 1993-04-27 Basf Aktiengesellschaft Thiophene derivatives
DE4236400A1 (de) * 1992-10-28 1994-05-05 Bayer Ag N-Phenylacetaminonitrile
EP0706527B1 (de) * 1993-07-02 2001-11-14 Bayer Ag Substituierte spiroheterocyclische 1h-3-aryl-pyrrolidin-2,4-dion-derivate, verfahren zu deren herstellung und deren verwendung als schädlingsbekämpfungsmittel
EP0973778A1 (en) 1997-03-07 2000-01-26 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
WO1999046267A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
WO2000014090A1 (en) 1998-09-02 2000-03-16 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[2,3-c]pyridine derivatives
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
GB0114185D0 (en) * 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
WO2002083649A1 (en) * 2001-04-11 2002-10-24 Senju Pharmaceutical Co., Ltd. Novel imidazolidinedione derivatives and use thereof as drugs
EP1383771A1 (en) * 2001-04-20 2004-01-28 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
CA2498399A1 (en) 2002-09-12 2004-03-25 Merck & Co., Inc. Method of treating diabetes and related conditions
CA2498106A1 (en) 2002-09-12 2004-03-25 Merck & Co., Inc. Substituted bicyclic thiophene derivatives, compositions containing such compounds and methods of use
US7196106B2 (en) * 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
CN100398533C (zh) 2008-07-02
BRPI0409454A (pt) 2006-05-02
AU2004230220A1 (en) 2004-10-28
JP4599347B2 (ja) 2010-12-15
CA2521732A1 (en) 2004-10-28
ATE418548T1 (de) 2009-01-15
JP2006523641A (ja) 2006-10-19
ES2316978T3 (es) 2009-04-16
KR100779324B1 (ko) 2007-11-28
RU2005135338A (ru) 2007-05-27
US7138529B2 (en) 2006-11-21
KR20060011959A (ko) 2006-02-06
US20040209943A1 (en) 2004-10-21
AU2004230220B2 (en) 2009-09-17
MXPA05010998A (es) 2005-12-12
WO2004092156A1 (en) 2004-10-28
EP1620425A1 (en) 2006-02-01
CN1774433A (zh) 2006-05-17
RU2336274C2 (ru) 2008-10-20
EP1620425B1 (en) 2008-12-24
CA2521732C (en) 2011-06-07
DE602004018630D1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
TW200505919A (en) DPP-IV inhibitors
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
WO2004013120A8 (en) Novel benzodioxoles
GB0625648D0 (en) Compounds
PL2029529T3 (pl) PODSTAWIONE PIROLIDYNONY JAKO INHIBITORY DEHYDROGENAZY 11-ß-HYDROKSYSTEROIDOWEJ TYPU 1
MX2009005358A (es) Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
MX2009003125A (es) Tiazol pirazolopirimidinas como antagonistas de receptor de crf1.
DE602004011394D1 (en) Thiazolderivate
GEP20104962B (en) Fused heterocyclic compounds
IL201317A0 (en) Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
MX2009005174A (es) Derivados de 5-sulfanilmetil-[1,2,4]triazol[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
TW200630374A (en) Thiazolyldihydroindazoles
TW200740787A (en) (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones
NO20080563L (no) Pyrazol[3,4-d]azepinderivater som histamin H3 antagonister
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
PL1828177T3 (pl) Nowi antagoniści receptora MCH
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
NO20070089L (no) DPP-IV inhibitorer
MX2008012093A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos.
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.